Hormonal
High body mass index (BMI) is a strong independent risk factor for the development of chronic kidney disease (CKD) and end-stage renal disease (ESRD), primarily driven by compensatory glomerular hyperfiltration and increased intraglomerular pressure.
Maintaining a healthy weight is one of the most effective ways to prevent kidney disease. High body weight forces your kidneys to work harder (hyperfiltration), which damages them over time. Focus on sustainable lifestyle changes like proper nutrition and exercise to lower your BMI, especially if you have high blood pressure or diabetes.
A high body mass index (BMI) is one of the strongest risk factors for new-onset chronic kidney disease. In individuals affected by obesity, a compensatory hyperfiltration occurs to meet the heightened metabolic demands of the increased body weight. The increase in intraglomerular pressure can damage the kidneys and raise the risk of developing chronic kidney disease in the long-term.
Why this rating
Based on numerous large population-based studies and meta-analyses cited in the text, though the paper itself is an editorial/review.
Source
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
Csaba P. Kövesdy et al. · Kidney Diseases · 2017
DOI 10.1159/000452965
More from this paper
- Weight loss interventions, including lifestyle changes and bariatric surgery, reduce blood pressure, glomerular hyperfiltration, and proteinuria in obese patients with CKD.Good
- Obesity increases the risk of nephrolithiasis (kidney stones) through mechanisms including lower urine pH, increased urinary oxalate, uric acid, and sodium excretion, as well as insulin resistance.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →